Study details
Enrolling now
Phase I/II Trial of NBTXR3 with Radiation and Immunotherapy
M.D. Anderson Cancer Center
NCT IDNCT05039632ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
40
Study length
about 2.7 years
Ages
18+
Locations
1 site in TX
What this study is about
This trial is testing a new treatment called NBTXR3, radiation therapy, and immunotherapy (Anti-PD-1/L-1) in people with advanced solid tumors that have spread to the lung or liver. The goal is to see if this combination can help control the disease.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Hafnium Oxide-containing Nanoparticles NBTXR3
- 2.Receive Radiation Therapy
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized (Open Label)
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Incidence of dose limiting toxicities, Objective response rate
Procedures
radiation